50CO **PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Sandman, et al.

Application No.: 0 9 /937,187   Group No.:

Filed: September 21, 2001   Examiner:

For: Surface Display of Selenocysteine-Containing Peptides ·

Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

(check and complete this item, if applicable)

1. ☒ This replies to the Office Letter dated __22 May 2002__ .

NOTE: If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the application number from the return post card or the attorney's docket number added.

☒ A copy of the Office Letter is enclosed.

CERTIFICATION UNDER 37 C.F.R. §§ 1.8(a) and 1.10*
(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

37 C.F.R. § 1.8(a)	37 C.F.R. § 1.10*
☐ with sufficient postage as first class mail.	☐ as "Express Mail Post Office to Addressee" Mailing Label No. _____ (mandatory)

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

Date: 52902

Signature

Melissa A. Jackson

(type or print name of person certifying)

WARNING: Each paper or fee filed by Express Mail must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. § 1.10(b).
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

IᴅENTIFICATION OF PERSON MAKING STATEMENT

2. I, ___Gregory D. Williams___

(type or print name of declarant signing below)

state the following:

ITEMS BEING SUBMITTED

3. Submitted herewith is/are:

    (check each item as applicable)

    A. ☒ "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. § 1.821(c) and 37 C.F.R. §§ 1.822 and 1.823.

    B. ☐ An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. § 1.821(d).

    C. ☒ A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. §§ 1.821(e) and 1.824.

    D. ☐ Please transfer to this application, in accordance with 37 C.F.R. § 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

    In re application of:

    Application No.: 0   /   Group No.:
    Filed: Examiner:
    For:

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Indentifier(s)" of the application as follows:

Computer Readable Form   "Sequence Identifier"

(other application)   (this application)

E. ☒ A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. § 1.821(g).

   ☐ Because the statement is not made by a person registered to practice before the Office, the statement is verified as required in 37 C.F.R. § 1.821(b).

F. ☒ Because this submission is made in fulfilling the requirement under 37 C.F.R. § 1.821(g), a statement that the submission includes no new matter.

   ☐ Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. § 1.821(g).

STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER

4. I hereby state:

(complete applicable item A and/or B)

A. ☒ Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.

B. ☒ All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

STATUS

5. Applicant is

☒ a small entity. A statement:

   ☐ is attached.

   ☒ was already filed.

☐ other than a small entity.

EXTENSION OF TERM

6.

NOTE: *"Extension of Time in Patent Cases (Supplement Amendments)—If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.*

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of Dec. 10, 1985 (1061 O.G. 34-35).

NOTE: *See 37 C.F.R. § 1.645 for extensions of time in interference proceedings and 37 C.F.R. § 1.550(c) for extensions of time in reexamination proceedings.*

7.   The proceedings herein are for a patent application and the provisions of 37 C.F.R. § 1.136 apply.

(complete (a) or (b) as applicable)

(a) ☐ Applicant petitions for an extension of time under 37 C.F.R. § 1.136
(fees: 37 C.F.R. § 1.17(a)(1)-(4)) for the total number of months checked below:

Extension (months)	Fee for other than small entity	Fee for small entity
☐ one month	$ 110.00	$ 55.00
☐ two months	$ 390.00	$ 195.00
☐ three months	$ 890.00	$ 445.00
☐ four months	$ 1,390.00	$ 695.00

Fee: $_____

If an additional extension of time is required, please consider this a petition therefor.

(check and complete the next item, if applicable)

☐ An extension for _____ months has already been secured. The fee paid therefor of $_____ is deducted from the total fee due for the total months of extension now requested.

Extension fee due with this request $_____

OR

(b) ☒ Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition for extension of time.

FEE PAYMENT

8. ☐ Attached is a ☐ check ☐ money order in the amount of $ _____

☐ Authorization is hereby made to charge the amount of $ _____

☐ to Deposit Account No. _____

☐ to Credit card as shown on the attached credit card information authorization form PTO-2038.

WARNING: Credit card information should not be included on this form as it may become public.

☒ Charge any additional fees required by this paper or credit any overpayment in the manner authorized above.

A duplicate of this paper is attached.

FEE DEFICIENCY

9.

NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO Finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, 1065 O.G. 31-33.

10. ☒ If any additional extension and/or fee is required, charge

☒ Deposit Account No. 14-0740

☐ Credit card as shown on the attached credit card information authorization form PTO-2038.

WARNING: Credit card information should not be included on this form as it may become public.

SIGNATURE(s)

Gregory D. Williams
_____
(type or print name of person signing statement)

_____
Signature

Date
32 Tozer Road
_____
P.O. Address of Signatory
Beverly, MA 01915

(if applicable)
Telephone No. (978) 927-5054 X:292
Reg. No. 30901
Customer No.: 28986

☐ Inventor(s)
☐ Assignee of complete interest
☐ Person authorized to sign on behalf of assignee
☒ Practitioner of record
☐ Filed under Rule 34(a)
☒ Registration No. 30901
☐ Other _____
(specify identity of declarant)

(complete the following, if applic

New England Biolabs, Inc.

(type name of assignee)

32 Tozer Road

Address of assignee

Beverly, MA 01915

Secretary

Title of person authorized to sign on behalf of
assignee

A "STATEMENT UNDER 37 C.F.R. § 3.73(b)" is attached.
Assignment recorded in PTO on ___September 21, 2001___
Reel ___012344___ Frame ___0412___

Reg. No.: 30901

Tel. No.: (978) 92705954 (292)

Customer No.: 28986

SIGNATURE OF PRACTITIONER
Gregory D. Williams
General Counsel
(type or print name of practitioner)
New England Biolabs, Inc.
32 Tozer Road
P.O. Address
Beverly, MA 01915

UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/937,187	Karen E Sandman	NEB -164-PUS

INTERNATIONAL APPLICATION NO.
PCT/US00/13292

I.A. FILING DATE	PRIORITY DATE
05/12/2000	

28986
NEW ENGLAND BIOLABS, INC.
32 TOZER ROAD
BEVERLY, MA 01915

CONFIRMATION NO. 4950
371 FORMALITIES LETTER

OC000000008136939

Date Mailed: 05/22/2002

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated Office (37 CFR 1.494):

- U.S. Basic National Fee
- Indication of Small Entity Status
- Assignee Statement
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration
- Request for Immediate Examination
- Small Entity Statement

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- The computer reada●rm that has been filed with this applicat●s been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- RAW SEQUENCE LISTING ERROR REPORT
- APPLICANT MUST PROVIDE:
  - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
  - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

  - For Rules Interpretation, call (703) 308-4216
  - To Purchase PatentIn Software, call (703) 306-2600
  - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

  - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

SHELBY J VIGIL

Telephone: (703) 305-3653

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/937,187	PCT/US00/13292	NEB -164-PUS

FORM PCT/DO/EO/916 (371 Formalities Notice)

Raw Sequence Listing Error Summary

| RROR DETECTED	SUGGESTED CORRECTION	SERIAL NUMBER: 09/937,187

TTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

1____Wrapped Nucleics
Wrapped Aminos

The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."

2____Invalid Line Length

The rules require that a line not exceed 72 characters in length. This includes white spaces.

3___Misaligned Amino
Numbering

The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.

4____Non-ASCII

The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.

5____Variable Length

Sequence(s)____contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.

5____PatentIn 2.0
"bug"

A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.

7____Skipped Sequences
(OLD RULES)

Sequence(s) ____ missing. If intentional, please insert the following lines for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
(i)   SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.

8____Skipped Sequences
(NEW RULES)

Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence.
<210> sequence id number
<400> sequence id number
000

____Use of n's or Xaa's
(NEW RULES)

Use of n's and/or Xaa's have been detected in the Sequence Listing.
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa; and which residue n or Xaa represents.

9____Invalid <213>
Response

Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence

____Use of <220>

Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32)   (Sec. 1.823 of Sequence Rules)

____PatentIn 2.0
"bug"

Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

____Misuse of n

n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.

AMC/MH – Biotechnology Systems Branch – 08/21/2001

S V

BIOTECHNOLOGY
SYSTEMS
BRANCH

RAW SEQUENCE LISTING
ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information
Center (STIC) detected errors when processing the following computer readable
form:

Application Serial Number: _09/937,187_

Source: _PCT/09_

Date Processed by STIC: _2/6/2002_

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:
1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE
APPLICANT, WITH A NOTICE TO COMPLY or,
2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A
NOTICE TO COMPLY
FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.
PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)
PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER
VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND
TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:
http://www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is
a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.
Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.
Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the
United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm> , EFS Submission
User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name,
Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,
2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,
Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

PCT/09

RAW SEQUENCE LISTING   DATE: 02/06/2002
PATENT APPLICATION: US/09/937,187   TIME: 18:41:31

Input Set : A:\Neb-164.app
Output Set: N:\CRF3\02062002\I937187.raw

pp 1-5

**Does Not Comply
Corrected Diskette Needed**

```
 3 <110> APPLICANT: SANDMAN, KAREN E.
 4        NOREN, CHRISTOPHER J.
 5        NEW ENGLAND BIOLABS, INC.
 7 <120> TITLE OF INVENTION: SURFACE DISPLAY OF SELENOCYSTEINE-CONTAINING PEPTIDES
 9 <130> FILE REFERENCE: NEB-164-PCT
11 <140> CURRENT APPLICATION NUMBER: US/09/937,187
12 <141> CURRENT FILING DATE: 2002-01-08
14 <150> PRIOR APPLICATION NUMBER: 60/134,286
15 <151> PRIOR FILING DATE: 1999-05-14
17 <160> NUMBER OF SEQ ID NOS: 42
19 <170> SOFTWARE: PatentIn Ver. 2.0
21 <210> SEQ ID NO: 1
22 <211> LENGTH: 38
23 <212> TYPE: RNA
24 <213> ORGANISM: Synthetic      see item 10 on Error Summary Sheet
26 <220> FEATURE:
27 <223> OTHER INFORMATION: N = A, G, C, or U
29 <220> FEATURE:
30 <223> OTHER INFORMATION: K = G and U
32 <400> SEQUENCE: 1
33 nnknnknnkn nkugannknn knnkucggcc gaaacaug                    38
35 <210> SEQ ID NO: 2
36 <211> LENGTH: 24
37 <212> TYPE: DNA
38 <213> ORGANISM: Synthetic     item 10
40 <400> SEQUENCE: 2
41 tcgtcttttc cttgaaagtc gcct                                   24
43 <210> SEQ ID NO: 3
44 <211> LENGTH: 24
45 <212> TYPE: DNA
46 <213> ORGANISM: Synthetic
48 <400> SEQUENCE: 3
49 aagtgtacgc tttgatctat gctg                                   24
51 <210> SEQ ID NO: 4
52 <211> LENGTH: 24
53 <212> TYPE: DNA
54 <213> ORGANISM: Synthetic
56 <400> SEQUENCE: 4
57 ttgcttttgc cttgaaatgt tctt                                   24
59 <210> SEQ ID NO: 5
60 <211> LENGTH: 24
61 <212> TYPE: DNA
62 <213> ORGANISM: Synthetic
```

RAW SEQUENCE LISTING   DATE: 02/06/2002
PATENT APPLICATION: US/09/937,187   TIME: 18:41:31

Input Set : A:\Neb-164.app
Output Set: N:\CRF3\02062002\I937187.raw

```
 64 <400> SEQUENCE: 5
 65 atgactacgc agtgaccttc tctg                                    24
 67 <210> SEQ ID NO: 6
 68 <211> LENGTH: 24
 69 <212> TYPE: DNA
 70 <213> ORGANISM: Synthetic
 72 <400> SEQUENCE: 6
 73 catattccgc cgtgaacgaa tcct                                    24
 75 <210> SEQ ID NO: 7
 76 <211> LENGTH: 24
 77 <212> TYPE: DNA
 78 <213> ORGANISM: Synthetic
 80 <400> SEQUENCE: 7
 81 aaggctctgt gttgacagga ttcg                                    24
 83 <210> SEQ ID NO: 8
 84 <211> LENGTH: 24
 85 <212> TYPE: DNA
 86 <213> ORGANISM: Synthetic
 88 <400> SEQUENCE: 8
 89 cttcttccgt gttgagctca gccg                                    24
 91 <210> SEQ ID NO: 9
 92 <211> LENGTH: 24
 93 <212> TYPE: DNA
 94 <213> ORGANISM: Synthetic
 96 <400> SEQUENCE: 9
 97 catcatccga cttgagctaa gcag                                    24
 99 <210> SEQ ID NO: 10
100 <211> LENGTH: 24
101 <212> TYPE: DNA
102 <213> ORGANISM: Synthetic
104 <400> SEQUENCE: 10
105 atgcctccta cgtgaatggc tacg                                    24
107 <210> SEQ ID NO: 11
108 <211> LENGTH: 24
109 <212> TYPE: DNA
110 <213> ORGANISM: Synthetic
112 <400> SEQUENCE: 11
113 aattggtttt cttgactgac tacg                                    24
115 <210> SEQ ID NO: 12
116 <211> LENGTH: 24
117 <212> TYPE: DNA
118 <213> ORGANISM: Synthetic
120 <400> SEQUENCE: 12
121 ctgcatccga cgtgagctcg gcct                                    24
123 <210> SEQ ID NO: 13
124 <211> LENGTH: 24
125 <212> TYPE: DNA
126 <213> ORGANISM: Synthetic
128 <400> SEQUENCE: 13
```

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/937,187

DATE: 02/06/2002
TIME: 18:41:31

Input Set : A:\Neb-164.app
Output Set: N:\CRF3\02062002\I937187.raw

```
129 gataggggc cttgagcgaa gatt                              24
131 <210> SEQ ID NO: 14
132 <211> LENGTH: 24
133 <212> TYPE: DNA
134 <213> ORGANISM: Synthetic
136 <400> SEQUENCE: 14
137 gcgtctttgc cttgaaggac gagt                              24
139 <210> SEQ ID NO: 15
140 <211> LENGTH: 24
141 <212> TYPE: DNA
142 <213> ORGANISM: Synthetic
144 <400> SEQUENCE: 15
145 ttgccgcgtc agtgatggtc tccg                              24
147 <210> SEQ ID NO: 16
148 <211> LENGTH: 24
149 <212> TYPE: DNA
150 <213> ORGANISM: Synthetic
152 <400> SEQUENCE: 16
153 ttgactggta cgtgatgtca gaat                              24
155 <210> SEQ ID NO: 17
156 <211> LENGTH: 24
157 <212> TYPE: DNA
158 <213> ORGANISM: Synthetic
160 <400> SEQUENCE: 17
161 gaggcgtcgc gttgatgttc gact                              24
163 <210> SEQ ID NO: 18
164 <211> LENGTH: 24
165 <212> TYPE: DNA
166 <213> ORGANISM: Synthetic
168 <400> SEQUENCE: 18
169 aagttggctc gttgatcggc gtcg                              24
171 <210> SEQ ID NO: 19
172 <211> LENGTH: 24
173 <212> TYPE: DNA
174 <213> ORGANISM: Synthetic
176 <400> SEQUENCE: 19
177 aatggggcgc agtgatcgag gcat                              24
179 <210> SEQ ID NO: 20
180 <211> LENGTH: 24
181 <212> TYPE: DNA
182 <213> ORGANISM: Synthetic
184 <400> SEQUENCE: 20
185 gcgagtccta cttgatttaa gccg                              24
187 <210> SEQ ID NO: 21
188 <211> LENGTH: 24
189 <212> TYPE: DNA
190 <213> ORGANISM: Synthetic
192 <400> SEQUENCE: 21
193 tgtgctcatc cgtgatctac tcgt                              24
```

```
195 <210> SEQ ID NO: 22
196 <211> LENGTH: 24
197 <212> TYPE: DNA
198 <213> ORGANISM: Synthetic
200 <400> SEQUENCE: 22
201 cagtcgacgc ggtgatggaa tgat                                    24
203 <210> SEQ ID NO: 23
204 <211> LENGTH: 24
205 <212> TYPE: DNA
206 <213> ORGANISM: Synthetic
208 <400> SEQUENCE: 23
209 attgtggagt cgtgattgaa tccg                                    24
211 <210> SEQ ID NO: 24
212 <211> LENGTH: 24
213 <212> TYPE: DNA
214 <213> ORGANISM: Synthetic
216 <400> SEQUENCE: 24
217 acgcagcgta tgtgattgcc gccc                                    24
219 <210> SEQ ID NO: 25
220 <211> LENGTH: 24
221 <212> TYPE: DNA
222 <213> ORGANISM: Synthetic
224 <400> SEQUENCE: 25
225 gtgcagtata cgtgattgcc gaag                                    24
227 <210> SEQ ID NO: 26
228 <211> LENGTH: 24
229 <212> TYPE: DNA
230 <213> ORGANISM: Synthetic
232 <400> SEQUENCE: 26
233 gctgggcagt cgtgatcgac tgat                                    24
235 <210> SEQ ID NO: 27
236 <211> LENGTH: 24
237 <212> TYPE: DNA
238 <213> ORGANISM: Synthetic
240 <400> SEQUENCE: 27
241 ctgtctgcga gtcgatcgca gttt                                    24
243 <210> SEQ ID NO: 28
244 <211> LENGTH: 8
245 <212> TYPE: PRT
246 <213> ORGANISM: Synthetic
248 <220> FEATURE:
249 <223> OTHER INFORMATION: At position 5, X = Selenocysteine
251 <400> SEQUENCE: 28
252 Ser Ala Arg Val Xaa His Gly Pro
253   1               5
256 <210> SEQ ID NO: 29
257 <211> LENGTH: 98
258 <212> TYPE: DNA
259 <213> ORGANISM: Synthetic
```

RAW SEQUENCE LISTING   DATE: 02/06/2002
PATENT APPLICATION: US/09/937,187   TIME: 18:41:31

          Input Set : A:\Neb-164.app
          Output Set: N:\CRF3\02062002\I937187.raw

```
 261 <400> SEQUENCE: 29
 262 catgtttcgg ccgtaccgac cgattggtgc agacctgcaa ccgatgggcc gtgtcagaca 60
 263 cgagcgctag agtgagaata gaaaggtacc cgggcatg                        98
 265 <210> SEQ ID NO: 30
 266 <211> LENGTH: 25
 267 <212> TYPE: DNA
 268 <213> ORGANISM: Synthetic
 270 <400> SEQUENCE: 30
 271 catgcccggg tacctttcta ttctc                                      25
 273 <210> SEQ ID NO: 31
 274 <211> LENGTH: 20
 275 <212> TYPE: DNA
 276 <213> ORGANISM: Synthetic
 278 <400> SEQUENCE: 31
 279 ccctcatagt tagcgtaacg                                            20
 281 <210> SEQ ID NO: 32
 282 <211> LENGTH: 10
 283 <212> TYPE: PRT
 284 <213> ORGANISM: Synthetic
 286 <220> FEATURE:
 287 <223> OTHER INFORMATION: At position 5, X = Selenocysteine
 289 <400> SEQUENCE: 32
 290 Ser Ala Arg Val Xaa His Gly Pro Ser Val
 291   1               5                   10
 294 <210> SEQ ID NO: 33
 295 <211> LENGTH: 85
 296 <212> TYPE: DNA
 297 <213> ORGANISM: Synthetic
 299 <220> FEATURE:
 300 <223> OTHER INFORMATION: M = A or C
 302 <220> FEATURE:
 303 <223> OTHER INFORMATION: N = A, C, T or G
 305 <400> SEQUENCE: 33
 306 catgtttcgg ccgattggtg cagacctgca accgamnnmn nmnntcamnn mnnmnnmnna 60
 307 gagtgagaat agaaaggtac ccggg                                      85
 309 <210> SEQ ID NO: 34
 310 <211> LENGTH: 85
 311 <212> TYPE: DNA
 312 <213> ORGANISM: Synthetic
 314 <220> FEATURE:
 315 <223> OTHER INFORMATION: M = A or C
 317 <220> FEATURE:
 318 <223> OTHER INFORMATION: N = A, C, T or G
 320 <400> SEQUENCE: 34
 321 catgtttcgg ccgattggtg cagacctgca accgamnnmn nmnatcamnn mnnmnnmnna 60
 322 gagtgagaat agaaaggtac ccggg                                      85
 324 <210> SEQ ID NO: 35
 325 <211> LENGTH: 8
 326 <212> TYPE: PRT
```

The prferace[?] [...] have been derrmed in the Sequence Listing.
[...] [...] [...] to insure a corresponding
explanation is presented in the <220> to <223> fields of
each sequence using n or Xaa.

VERIFICATION SUMMARY   DATE: 02/06/2002
PATENT APPLICATION: US/09/937,187   TIME: 18:41:32

Input Set : A:\Neb-164.app
Output Set: N:\CRF3\02062002\I937187.raw

```
:11  M:270 C: Current Application Number differs, Replaced Application Number
:12  M:271 C: Current Filing Date differs, Replaced Current Filing Date
:33  M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:1
:33  M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:1
:33  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
:252 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:28
:252 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:28
:252 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:28
:290 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:32
:290 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:32
:290 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
:306 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:33
:306 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:33
:306 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
:321 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:34
:321 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:34
:321 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:34
:383 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:40
:383 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:40
:383 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:40
:397 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:41
:397 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:41
:397 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:41
```